Prognostic effects of the expression of inhibitor of DNA‑binding family members on patients with lung adenocarcinoma

Lu,Xiaomin; Shao,Lili; Qian,Ye; Zhang,Yan; Wang,Yongsheng; Miao,Liyun; Zhuang,Zhixiang

doi:10.3892/ol.2020.12004

Prognostic effects of the expression of inhibitor of DNA‑binding family members on patients with lung adenocarcinoma

Authors:
- Xiaomin Lu
- Lili Shao
- Ye Qian
- Yan Zhang
- Yongsheng Wang
- Liyun Miao
- Zhixiang Zhuang
View Affiliations

Affiliations: Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China, Department of Oncology, Affiliated Haian Hospital of Nantong University, Nantong, Jiangsu 226601, P.R. China, Department of Respiratory Diseases, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, P.R. China
Published online on: August 21, 2020 https://doi.org/10.3892/ol.2020.12004
Article Number: 143
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The basic helix‑loop‑helix (bHLH) transcription factors are negatively regulated by inhibitor of DNA‑binding (ID) proteins. Several studies have demonstrated that ID family proteins are dysregulated in a variety of cancer types, including in lung adenocarcinoma (LUAD). In current study, the prognostic value of ID family members was evaluated by investigating publicly accessible databases, including Oncomine, Kaplan‑Meier plotter, UALCAN and the Human Protein Atlas. It was observed that the mRNA expression of all ID members was downregulated in LUAD tumor tissues compared with those in normal tissues according to the Oncomine and UALCAN databases. Additionally, increased mRNA expression levels of ID2 and ID1 were associated with improved and poorer survival time, respectively. Notably, ID3 and ID4 expression was not associated with survival in patients with LUAD. At the protein level, high ID2 significantly predicted an improved survival outcome while high ID1 is associated with shorter survival time. Thus, the results indicate that the ID proteins, particularly ID2, exhibit significant prognostic value in LUAD. More studies are required to elucidate the underlying molecular mechanisms behind the role of the ID family in the development of LUAD.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Cancer Genome Atlas Research Network, . Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
4	Johnson DH, Schiller JH and Bunn PA Jr: Recent clinical advances in lung cancer management. J Clin Oncol. 32:973–982. 2014. View Article : Google Scholar : PubMed/NCBI
5	Li P, Gao Q, Jiang X, Zhan Z, Yan Q, Li Z and Huang C: Comparison of clinicopathological features and prognosis between ALK rearrangements and EGFR mutations in surgically resected early-stage lung adenocarcinoma. J Cancer. 10:61–71. 2019. View Article : Google Scholar : PubMed/NCBI
6	Paesmans M: Prognostic and predictive factors for lung cancer. Breathe. 9:112–121. 2012. View Article : Google Scholar
7	Ke J, Wu R, Chen Y and Abba ML: Inhibitor of DNA binding proteins: Implications in human cancer progression and metastasis. Am J Transl Res. 10:3887–3910. 2018.PubMed/NCBI
8	Sikder HA, Devlin MK, Dunlap S, Ryu B and Alani RM: Id proteins in cell growth and tumorigenesis. Cancer Cell. 3:525–530. 2003. View Article : Google Scholar : PubMed/NCBI
9	Yokota Y: Id and development. Oncogene. 20:8290–8298. 2001. View Article : Google Scholar : PubMed/NCBI
10	Antonângelo L, Tuma T, Fabro A, Acencio M, Terra R, Parra E, Vargas F, Takagaki T and Capelozzi V: Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinomapatients treated with surgery and adjuvant chemotherapy. Exp Biol Med (Maywood). 241:1159–1168. 2016. View Article : Google Scholar : PubMed/NCBI
11	Zhou XL, Zeng, Ye YH, Sun SM, Lu XF, Liang WQ, Chen CF and Lin HY: Prognostic values of the inhibitor of DNA-binding family members in breast cancer. Oncol Rep. 40:1897–1906. 2018.PubMed/NCBI
12	Wen XF, Chen M, Wu Y, Chen MN, Glogowska A, Klonisch T and Zhang GJ: Inhibitor of DNA binding 2 inhibits epithelial-mesenchymal transition via upregulation of Notch3 in breast cancer. Transl Oncol. 11:1259–1270. 2018. View Article : Google Scholar : PubMed/NCBI
13	Lin HY, Zeng, Liang YK, Wei XL and Chen CF: GATA3 and TRPS1 are distinct biomarkers and prognostic factors in breast cancer: Database mining for GATA family members in malignancies. Oncotarget. 8:34750–34761. 2017. View Article : Google Scholar : PubMed/NCBI
14	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
15	Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM, et al: A subcellular map of the human proteome. Science. 356:eaal33212017. View Article : Google Scholar : PubMed/NCBI
16	Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
17	Nagy A, Lánczky A, Menyhárt O and Győrffy B: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 8:115152018. View Article : Google Scholar : PubMed/NCBI
18	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open- label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
19	Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
20	Shaw AT and Solomon BJ: Crizotinib in ROS1- rearranged non-small-cell lung cancer. N Engl J Med. 372:683–684. 2015. View Article : Google Scholar : PubMed/NCBI
21	Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B and Johnson BE: Dabrafenib plus trametinib in patients with previously untreated BRAF^V600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. Lancet Oncol. 18:1307–1316. 2017. View Article : Google Scholar : PubMed/NCBI
22	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
23	Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, et al: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019. View Article : Google Scholar : PubMed/NCBI
24	Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018. View Article : Google Scholar : PubMed/NCBI
25	McAllister SD, Christian RT, Horowitz MP, Garcia A and Desprez PY: Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther. 6:2921–2927. 2007. View Article : Google Scholar : PubMed/NCBI
26	Castañon E, Bosch-Barrera J, López I, Collado V, Moreno M, López-Picazo JM, Arbea L, Lozano MD, Calvo A and Gil-Bazo I: Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. J Transl Med. 11:132013. View Article : Google Scholar : PubMed/NCBI
27	Martini M, Cenci T, D'Alessandris GQ, Cesarini V, Cocomazzi A, Ricci-Vitiani L, De Maria R, Pallini R and Larocca LM: Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. Cancer. 119:1004–1012. 2013. View Article : Google Scholar : PubMed/NCBI
28	Thike AA, Tan PH, Ikeda M and Iqbal J: Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival. Histopathology. 68:702–712. 2016. View Article : Google Scholar : PubMed/NCBI
29	Bae WJ, Koo BS, Lee SH, Kim JM, Rho YS, Lim JY, Moon JH, Cho JH and Lim YC: Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamouscell carcinoma. Br J Cancer. 117:1810–1818. 2017. View Article : Google Scholar : PubMed/NCBI